Health Care [ 3/12 ] | Biotechnology [ 13/73 ]
NASDAQ | Common Stock
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients.
It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002 for solid tumors.
The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 25 | -1.90 Decreased by -171.43% | -0.73 Decreased by -160.27% |
| Mar 3, 25 | -0.60 Increased by +14.29% | -0.46 Decreased by -30.43% |
| Nov 15, 24 | -0.61 | -0.54 Decreased by -12.96% |
| Aug 14, 24 | -0.65 | -0.51 Decreased by -27.45% |
| May 8, 24 | -0.70 | -1.30 Increased by +46.00% |
| Mar 28, 24 | -0.70 | -1.10 Increased by +36.36% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by N/A% | -64.39 M Decreased by -269.68% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by N/A% | -20.63 M Increased by +2.64% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -20.56 M Decreased by -42.80% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -21.87 M Decreased by -1.42% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -17.42 M Decreased by -43.09% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -21.19 M Decreased by -102.96% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.40 M Decreased by -22.37% | Decreased by N/A% - |
| Jun 30, 23 | 0.00 Decreased by N/A% | -21.57 M Decreased by -193.51% | Decreased by N/A% - |